OPOCRIN GROUP

EXPERIENCE AND INNOVATION IN BIOLOGICAL APIs

Established in 1964, **Opocrin SpA** is a world leader in the research, production and marketing of APIs from biologically derived sources.

Our History

Through studying and processing heparins and its derivatives over a period years, Opocrin has gained competence and expertise in the field of thrombosis, cardiovascular and hematopoietic diseases and in the chemistry of polysaccharides in general. Since the beginning, the Opocrin R&aD team has developed numerous products that are approved by the scientific community and marketed by important pharmaceutical companies worldwide.

In 2020 Opocrin became Opocrin Group through the acquisition of LDO S.p.A. Opocrin becomes the top player in the field of Heparin derivatives and one of the main players in heparin business.

Opocrin Group through the acquisition carried out a backward vertical intergration (with the full control of heparin production process) and the diversification of the raw material sources. This strategy has been achieved thanks to the integration of the production plants (formerly LDO's plant) in Trino - Italy and Guanajuato - Mexico, and other investments in different countries. Mexico plant is producing the raw material starting from mucosa for the heparin process performed in the Trino plant.

Opocrin's policy has always been to firm put the spotlight on the following core values:

Focus on Customers' needs

The Opocrin staff is committed to providing the highest degree of efficiency and collaboration. Opocrin's primary aim lies in establishing long-term partnerships with its customers, not just selling APIs. Another key point for our company is offering our customers prompt technical, scientific, regulatory and sales services.

Research and Innovation

Taking advantage of its highly experienced background in the field of polysaccharides, Opocrin is able to develop new ideas and projects step by step. Opocrin believes that research and innovation add value and improve efficiency, productivity, quality and competitive market positioning. Opocrin recently increased its API lyophilization capacity for its own and customers' needs.

Quality and Regulatory Expertise

Our production plants have obtained AIFA, FDA, PMDA, ANVISA, Canadian Authority and KFDA approvals and operate in accordance with national, European and International standards and regulations. All checking, control and analysis procedures ensure the highest possible safety and quality standards in all production stages.

Contract-manufacturing Mission

Customers can choose Opocrin as a partner in the development of new products. We are strengthening our contract manufacturing area to full-key projects: from API batches for clinical trials to commercial production, focusing on laboratory services, process and product validation, development of analytical methods and regulatory support. In the last years, Opocrin has been supporting some customers in the development of new heparin-derived compounds, with no anticoagulant and antithrombotic activities, indicated for different therapeutic areas. Opocrin researchers are members of EP and USP panels working as experts for Heparin and Iron products.

OPOCRIN GROUP

Opocrin S.p.A.
Administrative and Executive Unit
Strada Scaglia Est, 5
41126 Modena
(MO) Italy
Ph. +39 059 558352
Fax +39 059 558211
E-mail info@opocrin.it
www.opocrin.it
VAT 00156140360

Opocrin S.p.A. Registered Office, Manufacturing Plant and R&D Centre
Via Pacinotti, 3
41043 Corlo di Formigine
(MO) Italy

Opocrin S.p.A.
Manufacturing Plant
Via Gazzate, 48
41015 Nonantola
(MO) Italy

LDO S.p.A.
Registered Office,
Strada Scaglia Est, 5
41126 Modena
(MO) Italy

LDO S.p.A.
Manufacturing Plant
SS 31/Bis
13039 Trino
(VC) Italy

PC Biologics,
S.A. de C.V.
Circuito Zelkova #4
Rancho Los Guantes
Valle de Santiago,
GTO. C.P. 38422
Mexico